Global Multiple Sclerosis Treatment Market Expected to Hit $31.55 Billion by 2029
New York, Tuesday, 1 July 2025.
The multiple sclerosis treatment market is poised for growth, driven by increased incidence rates and innovative therapies, reaching $31.55 billion by 2029 at a 4.8% CAGR.
Market Growth Driven by Advances in Treatment
The global multiple sclerosis treatment market is anticipated to grow from $24.86 billion in 2024 to $31.55 billion by 2029, with a compound annual growth rate (CAGR) of 4.8%[1]. This growth is driven by an increasing incidence of multiple sclerosis worldwide and advancements in treatment methodologies. Factors such as heightened awareness of early symptoms, access to disease-modifying therapies, and the rising preference for immunomodulatory treatments are contributing to this expansion[1].
Technological Innovations Shaping the Future
Future trends in the multiple sclerosis treatment market include leveraging technology-based remote monitoring, developing remyelination therapies, and integrating digital biomarkers and therapeutics[1]. These innovations are crucial as they cater to the increasing need for personalized and effective treatment options for patients suffering from neurological disorders. Companies are actively investing in research and innovation to enhance treatment efficacy and patient outcomes[1].
Emergence of Cost-effective Treatments
Adding to the transformative landscape, the introduction of a low-cost generic version of Tecfidera by Civicascript offers a substantial reduction in financial burden for many patients. Launched on June 29, 2025, this generic costs $47 per month for pharmacies and a maximum of $68 for patients, presenting significant savings compared to existing generic options[2]. This step is part of a broader initiative to make critical medications more accessible to those in need[2].
The Role of Key Industry Players
Major pharmaceutical companies like Johnson & Johnson, F. Hoffmann-La Roche, Merck & Co., and others are playing pivotal roles in the multiple sclerosis treatment market. These companies are not only focused on innovative drug development but are also at the forefront of advancing clinical understanding and therapeutics for multiple sclerosis[1]. Notably, Roche Pharma India introduced Ocrevus Ocrelizumab in February 2024, aimed at reducing inflammation and preventing immune assaults on nerve fibers, showcasing the ongoing commitment to combat this debilitating disease through advanced medication[1].